We describe the clinical and virological outcome of human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy (PML) treated with cytarabine. Twentyseven patients received intrathecal cytarabine, 5 received concomitant intravenous cytarabine, and 20 received concomitant antiretroviral therapy. The median baseline CD4
Objectives of the present work were to determine the clinical Progressive multifocal leukoencephalopathy (PML) is a suboutcome after treatment with intrathecal cytarabine with or acute demyelinating brain disorder, caused by the polyoma without antiretroviral drugs in a large series of patients with JC virus (JCV). PML occurs in immunocompromised hosts, AIDS-related PML and to establish the value of a semiquantitaincluding Ç5% of all patients with AIDS. Particularly in HIVtive assay for JCV DNA in CSF in monitoring treatment reinfected hosts, the clinical course is progressive and almost sponse. invariably fatal, although some cases of spontaneous remission have been described [1, 2] . There is no proven effective therapy for this condition. Anecdotal reports of response to cytosine Materials and Methods arabinoside (cytarabine) have neither been confirmed in larger series nor by a randomized clinical trial [3 -8] . In AIDS-related
Patients and treatments. Between 1 May 1993 and 31 April PML, remission or prolonged survival with antiretroviral ther-1997, 33 HIV-infected patients were diagnosed in vivo as havapy has also been described [9 -16] . Controversial data may ing PML at the Catholic University Department of Clinical in part depend on the fact that some of the reports included Infectious Diseases in Rome. Ten patients had a neuropathopatients with presumptive diagnoses based on suggestive MRI logic diagnosis made after brain biopsy, while the other 23 findings. PML is diagnosed definitely by histopathologic examwere diagnosed on the basis of typical MRI findings and JCV ination of brain tissue collected by brain biopsy or autoptically.
DNA detection by nested PCR of CSF drawn by lumbar puncMoreover, the detection of JCV DNA in CSF by a sensitive ture (clinicovirological diagnosis) [17, 18] . PCR has been proven to be highly predictive of a diagnosis of Patients were each enrolled in a prospective uncontrolled PML in patients with compatible MRI findings [17, 18] . Data study of treatment with cytarabine if their Karnofsky perforindicating whether this assay has value in monitoring the remance status score was §30. Twenty-seven patients were sponse of patients with PML to therapy are anecdotal [6, 19] . treated: 7 with neuropathologic and 20 with clinicovirological diagnosis. Four of these were included in a previous preliminary report [6] . granulocyte colony-stimulating factor (G-CSF) (3 mg/kg sc) on (800 g for 10 min) was done to clear samples if there were ú1,000 cells/mL of CSF. Ten microliters of CSF from each * And/or alteration of consciousness.
sample was used in PCR experiments without processing except for freeze-thawing. A nested PCR amplification was done with use of primers from the T-antigen region, specific for who received cytarabin are listed in table 1. All patients showed baseline neurological deficits: 7 had one focal sign, 18 had two JCV, as described [15] . The detection limit of the assay is 1,000 JCV DNA copies/mL of CSF.
to four focal signs, and 2 had more than four focal signs. The median Karnofsky performance status score was 50 (range, A semiquantitative estimate of the JCV DNA concentration in CSF was made by a slight modification of our previously 30 -80). The median CD4 / cell count was 28/mm 3 (range, 4 -191 cells/mm 3 ). For more than half of the patients, PML was described method [17] . Briefly, positive samples were serially diluted in sterile twice-distilled water in parallel with a serial the first AIDS-defining event. Of the 17 patients who had received antiretroviral therapy before the onset of PML, 15 had dilution of a known quantity of cloned JCV Mad-1 strain DNA. The last positive clinical sample dilution was multiplied by the had monotherapy with reverse transcriptase inhibitors and 2 had received combinations of two reverse transcriptase inhibi-JCV standard detection limit 1 100 to obtain the number of viral DNA copies per milliliter of each CSF sample.
tors.
Treatments and clinical response. All patients received inStatistical analyses. A paired t test was used to compare JCV loads at baseline and after 4 weeks, while values of groups trathecal cytarabine. The first 5 patients received concomitant intravenous cytarabine, and 20 of the 27 patients received conof clinically stable and progressed patients at different time points were compared by the Mann-Whitney U test for the comitant antiretroviral therapy. Thirteen patients received one nucleoside reverse transcriptase inhibitor (NRTI), 3 received nonparametric distribution of the data. Survival was analyzed by Kaplan-Meier product-limit estimate, and groups with diftwo NRTIs, and in 4 cases, two NRTIs plus indinavir were administered. Of the seven patients who were not given antiferent baseline characteristics were compared by the MantelCox test. ministrations of cytarabine: in six patients the treatment was There was no significant correlation between baseline CD4 / cell counts, a previous AIDS diagnosis, time from clinical onset discontinued early because of a rapid neurological deterioration or death. Treatments given to this evaluable group of patients, to diagnosis, baseline neurological picture, or previous or concomitant antiretroviral medication with clinical outcome at 4 toxicity, and clinical outcome are shown in table 2. The median number of iv cycles was three (range, two to four cycles). A weeks. As shown in table 3, a baseline Karnofsky score of ú50 was predictive of a significantly higher probability of median of five intrathecal courses (range, 3 -14 courses) were administered. Hematologic toxicity was the main adverse effect survival at 3 months after diagnosis. A previous exposure to antiretroviral therapy predicted a higher probability of survival observed. Overall, 13 (62%) of 21 patients developed hematologic toxicity of grade §3.
3 months after onset and after diagnosis. There was a trend toward better survival among patients with higher CD4 / cell At 4 weeks, 4 patients had a stable disease, while 15 showed neurological progression and 2 had died; none of the patients counts at diagnosis. One of the four patients showing stable disease at week 4 remained neurologically stable thereafter: he showed any improvement in their condition at this time. Three of the four stable patients progressed in the subsequent weeks. received a total of eight intrathecal administrations of cytarabine with a combination of two NRTIs. Neuroimaging showed The first follow-up neuroimaging was done for 10 patients at a median of 39 days (range, 13 -87 days) after the start of an initial progression but a subsequent stability until after 12 months. He died of bacterial pneumonia 403 days after the treatment and showed progression in 8 and stability in 2 patients. Three patients had subsequent neuroimaging studies diagnosis of PML. Virological evaluation. Fifteen of 21 clinically evaluable done, which showed stable lesions despite initial progression in two cases and further progression in one case. The median patients had at least one CSF sample each collected at baseline and week 4 and were therefore considered virologically evalusurvival from diagnosis (neuropathologically or virologically confirmed) in 20 evaluable patients was 66 days (25% -75% able. The baseline median JCV load in CSF was 3.6 log 10 copies/mL. At 4 weeks, the median JCV load was 4.3 log 10 interquartile range [IQR], 41 -82 days); 1 patient was lost to follow-up after 44 days. The median survival from the clinical copies/mL (increase of 0.7 log 10 copies/mL; P Å NS). At baseline, patients who had clinical progression after 4 onset of PML was 128 days (IQR, 74 -168 days). Progression of PML was the cause of death in 18 (90%) of 20 patients.
weeks showed a trend toward a higher mean JCV DNA concen-/ 9c63$$mr12 02-22-99 13:49:53 cida UC: CID Table 3 . Baseline variables, antiretroviral therapy, and probability naive and 00.01 log 10 copies/mL in pretreated patients;
of survival of 20 clinically evaluable patients.
P Å .006). Conversely, there was no significant correlation between the change in JCV concentration and antiretroviral 3-month survival probability treatment after the onset of PML (data not shown). prognosis. Nevertheless, our findings agree with results from the AIDS Clinical Trials Group 243 study in which patients in the antiretroviral therapy arm (which included a majority of patients taking combination therapy) had poor survival, as well tration in CSF than did patients who remained stable (mean { SD, 4.02 { 0.82 log 10 copies/mL vs. 3.38 { 0.54 log 10 as with other observations of failure of potent antiretroviral therapy, at least in some patients [8, 16, 20] . copies/mL; P Å .075). At 4 weeks, the JCV DNA level was significantly higher among progressors (mean { SD, 4.47 { On the other hand, previous antiretroviral exposure, mostly monotherapies in this series, was predictive of better survival. 0.76 log 10 copies/mL) than among stable patients (mean { SD, 3.47 { 0.57 log 10 copies/mL; P Å .027). Among the 11 patients This might be in agreement with the finding that more potent antiretroviral treatments significantly reduce the incidence of who progressed, the mean viral burden increased from baseline to 4 weeks (an increase of 0.45 log 10 copies/mL), although PML [21] and suggests a more important role for highly active antiretroviral therapy in the prevention rather than in the treatnot significantly. Patients whose conditions remained stable showed a stable virus load (increase of only 0.09 log 10 ment of this disorder. The semiquantitative determination of JCV load in CSF copies/mL). The three patients whose conditions were initially stable and then progressed after week 4 showed an increased showed interesting correlations with the clinical response to therapy. Patients with clinically stable disease after 4 weeks CSF JCV concentration after this time (data not shown). On the contrary, the CSF virus load from the only patient who of treatment had a trend toward a lower concentration of JCV DNA at baseline and had significantly lower levels of virus in had long-term stable disease became undetectable (JCV DNA, õ1,000 copies/mL) beginning from week 6 until his last lumbar CSF after 4 weeks than did patients showing clinical progression. Nevertheless, no viral concentration threshold was prepuncture, 12 months after the diagnosis of PML. Patients who were antiretroviral-naive before the onset of PML had a sigdictive of clinical evolution at 4 weeks or of survival. Subjects showing progression had a tendency to increase their viral nificant increase in JCV concentration after 4 weeks of treatment compared with that in patients who were receiving antiburden. Antiretroviral treatment before PML was associated with a stable JCV load, in agreement with the beneficial effect retrovirals before the onset of PML (mean difference from baseline JCV load, /0.85 log 10 copies/mL in antiretroviralon survival. On the contrary, patients without previous anti-/ 9c63$$mr12 02-22-99 13:49:53 cida UC: CID
